TRISTEL PLC

Management Reports • Sep 12, 2016

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4912J

Tristel PLC

12 September 2016

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014

Tristel plc

("Tristel" or the "Company")

Regulatory approval in Australia for surface disinfectant products

Tristel plc (AIM: TSTL), the manufacturer of infection control, contamination control and hygiene products, announces that it has received regulatory approval for its Fuse for Surfaces and Jet for Surfaces disinfectant products from the Therapeutic Goods Association (TGA), the body that regulates disinfectant use in Australia.  Both Tristel products have been approved as Hospital Grade Disinfectants and will be permitted to make efficacy claims against bacterial spores including Clostridium difficile.

The Australian hospital market constitutes 750 public hospitals and 290 private hospitals, and the problems associated with hospital-acquired infections in Australia are very similar to the United Kingdom.  In the UK, Fuse and Jet for Surfaces generated sales of approximately £1.2 million in the 2016 financial year.

Tristel has had a presence in the Australian hospital market since 2011 when it received its first approval from the TGA for its Wipes System for the disinfection of small medical instruments.  From 2011 to July 2016 Tristel sold its Wipes System via a distributor. During the year ended 30 June 2016 the distributor's sales of the Wipes System were approximately AU$3 million (c. £1.7 million). On 18 July Tristel purchased the distributor's business and established a direct presence in the Australian healthcare market via its wholly-owned subsidiary, Tristel Pty Limited.

Paul Swinney, CEO, commented: "Just as the Wipes System approval took nearly two years to obtain from the TGA, so has the approval for our two surface disinfection products. The wait will certainly be worthwhile as the advantages that our products enjoy in the United Kingdom are the same as they will enjoy in Australia.  Hospitals in Australia are experiencing infection outbreak problems as hospitals here have and, as we have repeatedly demonstrated, our surface disinfection products are widely recognised as the best defence against Clostridium difficile."

Click here for RNS Reach: "Success in controlling Clostridium difficile outbreaks" (24 April 2014) or view via this link: http://bit.ly/2c806WE

For further information please contact:       

## Tristel plc	Tel: 01638 721 500
Paul Swinney, Chief Executive Officer
Liz Dixon, Finance Director
Walbrook PR Ltd	Tel: 020 7933 8780 or [email protected]
Paul McManus	Mob: 07980 541 893
Lianne Cawthorne	Mob: 07584 391 303
finnCap	Tel: 020 7220 0500
Geoff Nash/ Giles Rolls (Corporate Finance)
Alice Lane (Corporate Broking)

This information is provided by RNS

The company news service from the London Stock Exchange

END

REAURVRRNVAKAAR